Biomarin Pharmaceutical Inc (BMRN) Hedge Fund & Institutional Holdings (Q2 2026)

BMRN ranks #1023 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

BMRN is a top-conviction position for Jones Hill Capital LP — at 17.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in BMRN belongs to BlackRock, Inc., but the position matters far more to Jones Hill Capital LP, who has 17.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fort Washington Investment Advisors Inc /oh/ has added to its BMRN position for two straight quarters, increasing it by $2.4M to reach $42.7M today.

Assenagon Asset Management S.A. has trimmed its BMRN position for two straight quarters, cutting it by $28.1M while still holding $80.4M.

BMRN is down 2.4% today, but institutions show net buying of $1.6B this quarter — a divergence between today's price move and the underlying institutional flow.

BMRN posted net income of $73.0M over the trailing twelve months, and currently trades at a P/E of 147.9.

• Profitable — net income of $73.0M over the trailing twelve months
• Revenue grew 11.2% year over year
• Net income declined year over year, from $657.2M to $73.0M
• Generated $828.0M in positive operating cash flow
• Current ratio of 5.21x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.25x equity — within a conventional range